A more recent study showed that treatment with a COX-2 selective inhibitor etoricoxib reduced the aromatase protein and estrogen levels and decreased the incidence of mammary tumors in high-sugar/fat-fed mice [81]. The gene discussed is CYP19A1; the disease is breast cancer.